Renovaro Biosciences Inc. (RENB)

Renovaro Biosciences Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Year Ending	TTM	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019
Cash & Equivalents	0.31	1.87	9.17	20.66	8.7	12.28
Cash & Cash Equivalents	0.31	1.87	9.17	20.66	8.7	12.28
Cash Growth	-89.39%	-79.56%	-55.61%	137.62%	-29.20%	-21.27%
Receivables	0	0	0	0	0	0.02
Other Current Assets	0.91	0.69	0.39	0.23	0.24	0.19
Total Current Assets	1.22	2.57	9.57	20.9	8.94	12.49
Property, Plant & Equipment	1.87	1.42	1.74	2.16	2.48	0.69
Goodwill and Intangibles	209.16	54.29	73.26	166.53	166.54	166.56
Other Long-Term Assets	0.02	0.02	0.07	0.02	0.14	0.14
Total Long-Term Assets	211.06	55.74	75.07	168.71	169.16	167.38
Total Assets	212.28	58.3	84.63	189.61	178.1	179.88
Accounts Payable	7.99	5.3	1.4	0.32	0.59	0.77
Current Debt	7.6	4.82	1.45	0.29	0.27	0
Other Current Liabilities	5.28	0.91	3.6	1.27	0.47	0.34
Total Current Liabilities	20.87	11.02	6.45	1.89	1.33	1.11
Long-Term Debt	0.97	0.78	5.56	7.02	7.31	0
Other Long-Term Liabilities	21.84	0	0	6.04	3.18	5.67
Total Long-Term Liabilities	22.81	0.78	5.56	13.06	10.5	5.67
Total Liabilities	43.68	11.8	12.01	14.94	11.83	6.78
Total Debt	8.57	5.59	7.02	7.31	7.58	0
Debt Growth	21.84%	-20.27%	-4.03%	-3.60%	-	-
Retained Earnings	-274.76	-244.03	-204.35	-90.91	-64.19	-52.77
Comprehensive Income	1.03	-0.03	-0.03	-0.01	-0.04	0.1
Shareholders' Equity	168.6	46.5	72.62	174.66	166.27	173.1
Net Cash / Debt	-8.26	-3.72	2.16	13.35	1.11	12.28
Net Cash / Debt Growth	-	-	-83.86%	1100.31%	-90.94%	-21.27%
Net Cash Per Share	-0.08	-0.07	0.04	0.28	0.02	0.33
Working Capital	-19.65	-8.46	3.11	19.01	7.61	11.38
Book Value Per Share	1.57	0.83	1.38	3.70	3.59	4.61

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).